Asia
There’s plenty of news coming out of the American Society of Clinical Oncology (ASCO) Annual Meeting behind held in Chicago. Here’s a look at a few more of the top stories.
There are plenty of great scientific research stories out this week from a tool to delete gene products to the growth of whole muscles incorporated into a biohybrid robot. Here’s a look at just a few of them.
Following the long holiday weekend, three pharma companies began the week with good news as the U.S. Food and Drug Administration awarded their therapies with Priority Review Status.
Brii Biosciences is launching to accelerate the development and delivery of breakthrough drugs in China with $260 million in financial backing.
With a new chief executive officer on board, GRAIL, Inc. has secured a whopping $300 million in an oversubscribed Series C financing round led by multiple Chinese investment groups.
On May 19 every year the people who are afflicted with IBD disorders unite across the globe to raise awareness of the disease and urge governments and healthcare systems to continue to focus on the development of necessary treatments.
The 2017/2018 influenza season was considered one of the worst, made more so by the ineffectiveness of the season’s flu vaccine. The FDA is focusing partially on simply determining why this year’s flu vaccine missed the mark.
Two years after entering into a licensing relationship Canada-based Zymeworks Inc. and Japanese pharma giant Daiichi Sankyo have entered into a second licensing agreement to expand immuno-oncology research with bispecific antibodies.
Shares of Chinese pharmaceutical and medical device company WuXi AppTec were a hot commodity Tuesday as the company made its debut on the Shanghai Stock Exchange. Another Chinese company, Ascletis Pharma, also chose a new stock listing.
Shares of Adocia are up nearly 30 percent this morning after the company announced it granted exclusive development and commercialization rights of its insulin products to Tonghua Dongbao Pharmaceuticals.
PRESS RELEASES